ABSTRACT
Jeff Kindler, CEO of Pfizer, pondered over sales of Lipitor. The drug had brought in $12.7 billion in revenues in 2007.2 This blockbuster belonged to a group of drugs called statins that reduce the level of cholesterol in the body by inhibiting the process by which the body produces cholesterol. What was it about Lipitor and Pfizer that had enabled the drug to do so well? Could Pfizer or any pharmaceutical company ever repeat such a feat?
